The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen

S

Siriraj Hospital

Status

Not yet enrolling

Conditions

CMV Infection or Reactivation After Allogenic HSCT

Study type

Observational

Funder types

Other

Identifiers

NCT06362720
720/2566(IRB2)

Details and patient eligibility

About

The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen. The main questions it aims to answer are: How do CMV infection and reactivation differ between Allo-SCT patients who received a standard regimen versus those who received a Post-transplant Cyclophosphamide-based regimen? progression-free survival, Median overall survival, cumulative incidence of relapse, non-relapsed mortality (NRM) and GvHD at 2 years after Allo-SCT The impact of CMV infection and CMV reactivation on progression-free survival, overall survival, and NRM Averse events of GVHD prophylaxis medication Participants will be collected the data of treatment and treatment response during transplant until 2 years after transplant from hospital medical record.

Enrollment

158 estimated patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age more than 15 years
  • Diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), myelofibrosis primary and/or post PV/ET myelofibrosis, aplastic anemia, lymphoma, or paroxysmal nocturnal hemoglobinuria
  • Received HLA-matched related (MSD-HSCT) or unrelated allo-SCT (MUD-HSCT) or haploidentical hematopoietic stem cell transplantation

Exclusion criteria

Insufficient data needed for analysis

Trial design

158 participants in 2 patient groups

standard GVHD prophylaxis
Description:
calcineurin inhibitor (cyclosporin A ;CSA) and methotrexate (MTX)
posttransplant cyclophosphamide (PTCy)

Trial contacts and locations

0

Loading...

Central trial contact

Chutima Kunacheewa, MD; Weerapat Owatthanapanich, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems